Oncology Blood Testing Market is expected to grow significantly through 2032

Posted by Ganesh Shinde on April 12th, 2023

The global oncology blood testing market is anticipated to be worth US$ 3,851.7 million in 2022, rising to US$ 18,278.2 million by 2032. Throughout the forecast period, the market is expected to increase at a CAGR of 15.2%.

Companies offer diverse molecular decision support systems that combine genomic and clinical data to close gaps in precision medicine practise, increasing demand for oncology blood testing. Because of the most recent research and breakthroughs in oncology blood testing, researchers were able to diagnose genetic mutations of various tumours.

The ability to detect malignant cells through enhanced human genome sequencing increases the market share of oncology blood testing. The rising number of cancer diagnoses drives up research spending, propelling the oncology blood testing market size even further. The spike in technological innovation and improvements is driving the expansion of the cancer blood testing market through 2031.

With a revenue share of 52.6% in 2022, North America dominates the oncology blood testing market.

This is due to favourable payment regulations, an increase in cancer incidence among the population, and increased knowledge about early cancer detection. This region has a high demand for oncology blood testing and advanced cancer prevention, diagnosis, and treatment technologies.

Competitive Landscape

Some of the key market participants in the oncology blood testing market are Guardant Health Inc., Trovagene Inc., Genomic Health Inc., Foundation Medicine Inc., Exosome Diagnostics, Pathway Genomics Corporation, F. Hoffman-La Roche Ltd., Abbott Laboratories, EntroGen Inc., Qiagen N.V., Cepheid, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Illumina Inc., CORE Diagnostics, Genoptix Inc., GenPath, NeoGenomics Laboratories Inc., Siemens, MolecularMD, ArcherDx Inc., ARUP Laboratories., Invivoscribe Inc., GenPath, Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., Roche Holding A.G., Invitae Corporation, Asuragen Inc., Molecularmd, EntroGen, Cepheid, Cancer Genetics, Adaptive Biotechnologies, Grail, Abingdon Health, Freenome, Vivia Biotech, Biofluidica, SkylineDX, Biodesix Inc., NovellusDX, BioNTech SE, etc

Browse Detail Summary Of Research Report@ https://www.futuremarketinsights.com/reports/oncology-blood-testing-market